BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 11849247)

  • 1. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
    Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer.
    Patócs A; Valkusz Z; Igaz P; Balogh K; Tóth M; Varga I; Rácz K
    Clin Genet; 2003 Mar; 63(3):219-23. PubMed ID: 12694233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.
    González-Yebra B; Medrano ME; Mantilla A; Palma V; Colin C; Hernández DM; Tapia J; Dawson B; Salcedo M
    Endocr Pathol; 2003; 14(1):71-80. PubMed ID: 12746565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma.
    Da Silva AM; Maciel RM; Da Silva MR; Toledo SR; De Carvalho MB; Cerutti JM
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5438-43. PubMed ID: 14602786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation.
    Papi G; Corrado S; Pomponi MG; Carapezzi C; Cesinaro A; LiVolsi VA
    Endocr Pathol; 2003; 14(3):269-76. PubMed ID: 14586073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism.
    Rotondi M; Ercolino T; Fonte R; Lagonigro MS; Leporati P; Villani L; La Manna L; Mannelli M; Chiovato L
    J Endocrinol Invest; 2009 Feb; 32(2):115-8. PubMed ID: 19411807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid carcinomas involving follicular and parafollicular C cells: seventeen cases with characterization of RET oncogenic activation.
    Vantyghem MC; Pigny P; Leteurtre E; Leclerc L; Bauters C; Douillard C; D'Herbomez M; Carnaille B; Proye C; Wemeau JL; Lecomte-Houcke M
    Thyroid; 2004 Oct; 14(10):842-7. PubMed ID: 15588381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation.
    Jung J; Uchino S; Lee Y; Park H
    J Korean Med Sci; 2010 Feb; 25(2):226-9. PubMed ID: 20119574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
    Griffith C; Zhang S; Mukhopadhyay S
    Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.
    Dvorakova S; Vaclavikova E; Duskova J; Vlcek P; Ryska A; Bendlova B
    J Endocrinol Invest; 2005 Nov; 28(10):905-9. PubMed ID: 16419493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance.
    Heshmati HM; Gharib H; Khosla S; Abu-Lebdeh HS; Lindor NM; Thibodeau SN
    Mayo Clin Proc; 1997 May; 72(5):430-6. PubMed ID: 9146685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC.
    Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M
    Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.